Literature DB >> 21533910

Serious upper gastrointestinal complications of NSAIDs and COX-2 selective agents.

Guy Sisson, Ingvar Bjarnason.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21533910     DOI： 10.1007/s10787-011-0085-5

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN： 0925-4692            Impact factor:   4.473


× No keyword cloud information.
  26 in total

1.  Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study.

Authors:  Gaurav Arora; Gurkirpal Singh; Shweta Vadhavkar; Shamita B Shah; Ajitha Mannalithara; Alka Mithal; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2010-04-29       Impact factor: 3.199

2.  Non-steroidal anti-inflammatory drugs request parity with Helicobacter pylori.

Authors:  Meera Ladwa; Ken Takeuchi; Ingvar Bjarnason
Journal:  Scand J Gastroenterol       Date:  2006-04       Impact factor: 2.423

Review 3.  Non steroidal anti-inflammatory drugs, cyclooxygenase selectivity and gastrointestinal toxicity.

Authors:  M Jacob; R Simpson; I Bjarnason
Journal:  Ital J Gastroenterol Hepatol       Date:  1998-02

4.  Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding.

Authors:  D W Kaufman; J P Kelly; J E Sheehan; A Laszlo; B E Wiholm; L Alfredsson; R S Koff; S Shapiro
Journal:  Clin Pharmacol Ther       Date:  1993-04       Impact factor: 6.875

5.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

Review 6.  Gastroprotection and nonsteroidal anti-inflammatory drugs (NSAIDS). Rationale and clinical implications.

Authors:  J Hayllar; A Macpherson; I Bjarnason
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

7.  Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

Authors:  Francis K L Chan; Angel Lanas; James Scheiman; Manuela F Berger; Ha Nguyen; Jay L Goldstein
Journal:  Lancet       Date:  2010-06-16       Impact factor: 79.321

8.  Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

Authors:  S G Morham; R Langenbach; C D Loftin; H F Tiano; N Vouloumanos; J C Jennette; J F Mahler; K D Kluckman; A Ledford; C A Lee; O Smithies
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

9.  COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.

Authors:  Gudmundur Sigthorsson; Robert J Simpson; Matthew Walley; Andrew Anthony; Russell Foster; Christoph Hotz-Behoftsitz; Abbas Palizban; Joaquim Pombo; Jo Watts; Scott G Morham; Ingvar Bjarnason
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

Review 10.  Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use.

Authors:  M J Langman
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.